Combined Modality Therapy ; methods ; trends ; Heart Defects, Congenital ; therapy ; Humans

Gastric cancer remains one of the most common causes of cancer-related death in China. Radical operation is the only potentially curative therapy for advanced gastric cancer (AGC). D2 radical gastrectomy has been widely accepted as a standard surgical procedure for patients with AGC in China. Several clinical trials have revealed that more extended resection than D2 surgery has no impact on survival. In order to improve the prognosis of AGC patients, it is necessary to carry out the preoperative TNM staging for selecting a reasonable therapeutical modality before surgery. Multimodality treatment involving perioperative chemotherapy, radiotherapy or molecular targeting agents in addition to surgery have been thought to be promising treatment strategy. In this article, we present an update on the current literature regarding the trends of surgical multimodal treatment for the patients with AGC.
Combined Modality Therapy ; trends ; Humans ; Stomach Neoplasms ; surgery

Gastric cancer is a common type of malignant tumors, but its clinical prognosis remains unsatisfactory. Up to 2020, a growing number of high-quality clinical researches has provided reliable evidence for clinical practice. Evidences from surgery, perioperative treatment and immunotherapy, such as changes in surgical methods, improvement of perioperative chemotherapy and combination of immune and chemotherapy strategy, provided the possibility to improve the clinical efficacy of gastric cancer. In our clinical practice, gastrointestinal surgeons need to integrate the current research progression and develop individualized strategy for different patients, which is expected to further improve the prognosis and quality of life for patients with gastric cancer.
Biomedical Research/trends* ; Combined Modality Therapy ; Gastrectomy ; Humans ; Prognosis ; Quality of Life ; Stomach Neoplasms/therapy*

Strategies in comprehensive therapy for gastrointestinal (GI) cancer have been optimized in the last decades to improve patients' outcomes. However, treatment options remain limited for late-stage or refractory diseases. The efficacy of immune checkpoint inhibitors (ICIs) for treatment of refractory GI cancer has been confirmed by randomized clinical trials. In 2017, pembrolizumab was approved by the US Food and Drug Administration as the first agent for treatment of metastatic solid tumors with mismatch repair deficiency, especially for colorectal cancer. Given the different mechanisms, oncologists have focused on determining whether ICIs-based combination strategies could achieve higher efficacy than conventional therapy alone in late-stage or even front-line treatment of GI cancer. This review discusses the current status of combining immune checkpoint inhibitors with molecular targeted therapy, chemotherapy, or radiotherapy in GI cancer in terms of mechanisms, safety, and efficacy to provide basis for future research.
Combined Modality Therapy ; methods ; Gastrointestinal Neoplasms ; immunology ; therapy ; Humans ; Immunotherapy ; methods ; trends ; Randomized Controlled Trials as Topic

Biomedical Research ; methods ; trends ; China ; Combined Modality Therapy ; Humans ; Management Information Systems ; trends ; Multicenter Studies as Topic ; Pancreatic Neoplasms ; therapy

Combined Modality Therapy ; Female ; Genital Neoplasms, Female ; radiotherapy ; surgery ; Gynecology ; education ; trends ; Humans ; Medical Oncology ; education ; trends

The comprehensive treatment of colorectal cancer has been quickly progressing in recent years, and TCM treatment plays an active role in the postoperative management of colorectal cancer. In this paper, the progress of postoperative management of colorectal cancer with integrative medicine was reviewed to provide a reference for guiding the researches on this topic.
Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Colorectal Neoplasms ; drug therapy ; surgery ; Combined Modality Therapy ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Humans ; Phytotherapy ; Postoperative Care ; methods ; trends

Local advanced gastric cancer (LAGC) accounts for a large proportion of annual newly diagnosed gastric cancer patients in China. There is a general consensus for D2 radical gastrectomy followed by postoperative adjuvant chemotherapy for LAGC patients, and this therapeutic strategy has been confirmed by a series of clinical trials to obviously improve the patients' prognosis; however, the recurrence rate is still high (about 50%-80% in advanced stage), which makes it difficult to further improve the long-term survival. Perioperative therapy, especially whether preoperative neoadjuvant therapy (NAT) can improve the efficacy of patients with LAGC, has been paid more and more attention. NAT is mainly defined as a preoperative chemotherapy or chemoradiotherapy, aiming at increasing curative resection rate by downstaging tumor, eliminating micrometastases, and autologously testing of anti-cancer drug sensitivity etc. However, there are still some controversy whether LAGC patients could gain survival benefit from NAT and also lack of general consensus for this issue. In this paper, the author reviews and analyzes the current situation of perioperative therapies for LAGC patients, especially emphasize the results of neoadjuvant chemotherapy or chemoradiotherapy reported by various high-level clinical studies. The preliminary effect of perioperative chemotherapy combined with molecular targeted or immunotherapy has also aroused great interest and attention. While we continue to carry out NAT and look forward to more new high-level evidence trials on NAT, we must emphasize again that R0 gastrectomy remains the most important therapeutic modality for the patients with LAGC.
Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Chemoradiotherapy ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Gastrectomy/methods* ; Humans ; Lymph Node Excision ; Neoadjuvant Therapy ; Neoplasm Staging ; Perioperative Care/trends* ; Stomach Neoplasms/therapy*

China ; Combined Modality Therapy ; standards ; trends ; Facial Neoplasms ; therapy ; Humans ; Maxillary Neoplasms ; therapy ; Medicine, Chinese Traditional ; methods ; Mouth Neoplasms ; therapy ; Oral Surgical Procedures ; methods

Hepatocellular carcinoma (HCC) is the second most common cause of cancer death worldwide. This cancer commonly arises against a background of chronic liver disease. As a result, a patient with HCC requires multidisciplinary care. Treatment options vary widely based on tumor burden and metastases. The most widely utilized staging system is the Barcelona Clinic Liver Cancer staging system, which recommends treatments based on tumor size and the underlying liver disease and functional status of the patient. Treatment options range from surgical resection or transplantation to locoregional therapies with modalities such as radiofrequency ablation and transarterial chemoembolization to systemic chemotherapies. Future care involves the development of combination therapies that afford the best tumor response, further clarification of the patients best suited for therapies and the development of new oral chemotherapeutic agents.
Antineoplastic Agents/therapeutic use ; Carcinoma, Hepatocellular/pathology/*therapy ; Catheter Ablation/trends ; Chemoembolization, Therapeutic/trends ; Combined Modality Therapy/trends ; Forecasting ; Humans ; Liver Neoplasms/pathology/*therapy ; Liver Transplantation ; Neoplasm Staging/methods